Oscar Health (OSCR) Q2 2026 Earnings Call Transcript
Oscar Health (OSCR) reported Q2 2026 revenue of $4.9B, up 70% year over year, and net income of $362M. Effectuated membership rose to 2.96M, and medical loss ratio improved to 79.2%. Management reiterated full-year revenue guidance of $18.7B to $19.0B and raised earnings from operations guidance to $500M to $700M, citing disciplined pricing and favorable prior-period reserves, while noting potential higher churn from CMS eligibility verification.
How this was made
The 30-second read
Why it matters
The key tradable elements are the raised full-year earnings from operations guidance, improved MLR and SG&A ratio, and the explicit risk that churn could be closer to 2% as CMS eligibility verification tightens.
Market read
Guidance and margin metrics are likely to drive near-term positioning, while churn and outpatient utilization risks can cap upside if 2H trends deteriorate.
What to watch
Outpatient utilization was described as elevated through the first six months, and only a small portion of favorable 2026 morbidity data was recognized in the updated outlook, leaving room for estimate volatility.
Background
Oscar Health’s Q2 2026 earnings call highlights strong membership growth, margin improvement, and an ICHRA strategy expansion via its ICHRAx platform.
Ticker impact
Oscar Health reported Q2 2026 revenue of $4.9B (+70% YoY) and raised full-year earnings from operations guidance to $500M-$700M.
Near-term bias positive on margin/guidance, with downside risk if churn or outpatient utilization worsens in 2H.
The article provides multiple quantified operating metrics (MLR 79.2%, SG&A ratio 14.2% record low) and a specific full-year outlook update, offset by explicit risk commentary on churn potentially doubling.
Market effects
Reinforces that ACA/individual and ICHRA-focused insurers can benefit from pricing discipline and tech-driven operating leverage, while CMS program integrity remains a key swing factor.
Primarily US healthcare insurance market sentiment, with potential read-through to other ACA and ICHRA-adjacent carriers.
Limited direct global impact; mostly affects US managed care/health insurance risk appetite.
Counterpoint
The improved MLR and reserve development may not fully persist, and management’s churn warning implies membership growth could decelerate or reverse in 2H.
Key entities
- companyOscar Health, Inc.
US health insurer reporting Q2 2026 results and updated full-year guidance, including improved MLR and record-low SG&A ratio.
- personMark Bertolini
CEO discussing utilization trends, AI-driven platform advantages, and churn risk tied to CMS eligibility verification.
- personScott Blackley
CFO providing guidance details and warning that churn may be closer to twice prior expectations.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Federal agency whose program integrity and eligibility verification processes management says may accelerate churn.
